vs
Apellis Pharmaceuticals, Inc.（APLS）与奥飞娱乐（MAX）财务数据对比。点击上方公司名可切换其他公司
奥飞娱乐的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$310.0M vs $199.9M），奥飞娱乐净利率更高（4.5% vs -29.5%，领先34.0%），奥飞娱乐同比增速更快（17.3% vs -5.9%），过去两年奥飞娱乐的营收复合增速更高（31.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
奥飞娱乐股份有限公司由蔡东青于1993年创立，是一家中国跨国综合企业集团，主营动漫、玩具、传媒资产与娱乐业务，2016年由原奥飞动漫更名而来。集团拥有国漫平台有妖气，还在美国设有影视公司奥飞影业，并宣布将在美国设立动漫业务部门。
APLS vs MAX — 直观对比
营收规模更大
MAX
是对方的1.6倍
$199.9M
营收增速更快
MAX
高出23.2%
-5.9%
净利率更高
MAX
高出34.0%
-29.5%
两年增速更快
MAX
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $310.0M |
| 净利润 | $-59.0M | $14.0M |
| 毛利率 | — | 15.1% |
| 营业利润率 | -25.6% | 7.2% |
| 净利率 | -29.5% | 4.5% |
| 营收同比 | -5.9% | 17.3% |
| 净利润同比 | -62.2% | 701.8% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSMAX
| Q1 26 | — | $310.0M | ||
| Q4 25 | $199.9M | $291.2M | ||
| Q3 25 | $458.6M | $306.5M | ||
| Q2 25 | $178.5M | $251.6M | ||
| Q1 25 | $166.8M | $264.3M | ||
| Q4 24 | $212.5M | $300.6M | ||
| Q3 24 | $196.8M | $259.1M | ||
| Q2 24 | $199.7M | $178.3M |
净利润APLSMAX
| Q1 26 | — | $14.0M | ||
| Q4 25 | $-59.0M | $31.4M | ||
| Q3 25 | $215.7M | $14.9M | ||
| Q2 25 | $-42.2M | $-18.7M | ||
| Q1 25 | $-92.2M | $-1.9M | ||
| Q4 24 | $-36.4M | $4.6M | ||
| Q3 24 | $-57.4M | $9.5M | ||
| Q2 24 | $-37.7M | $3.6M |
毛利率APLSMAX
| Q1 26 | — | 15.1% | ||
| Q4 25 | — | 15.4% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 15.0% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 17.8% |
营业利润率APLSMAX
| Q1 26 | — | 7.2% | ||
| Q4 25 | -25.6% | 7.7% | ||
| Q3 25 | 48.7% | 6.4% | ||
| Q2 25 | -18.6% | -8.0% | ||
| Q1 25 | -50.0% | 0.0% | ||
| Q4 24 | -12.3% | 6.1% | ||
| Q3 24 | -24.0% | 6.0% | ||
| Q2 24 | -14.7% | 3.6% |
净利率APLSMAX
| Q1 26 | — | 4.5% | ||
| Q4 25 | -29.5% | 10.8% | ||
| Q3 25 | 47.0% | 4.9% | ||
| Q2 25 | -23.6% | -7.4% | ||
| Q1 25 | -55.3% | -0.7% | ||
| Q4 24 | -17.1% | 1.5% | ||
| Q3 24 | -29.2% | 3.7% | ||
| Q2 24 | -18.9% | 2.0% |
每股收益（稀释后）APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $0.50 | ||
| Q3 25 | $1.67 | $0.26 | ||
| Q2 25 | $-0.33 | $-0.33 | ||
| Q1 25 | $-0.74 | $-0.04 | ||
| Q4 24 | $-0.30 | $0.09 | ||
| Q3 24 | $-0.46 | $0.17 | ||
| Q2 24 | $-0.30 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $26.1M |
| 总债务越低越好 | — | $163.5M |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $367.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSMAX
| Q1 26 | — | $26.1M | ||
| Q4 25 | $466.2M | $46.9M | ||
| Q3 25 | $479.2M | $38.8M | ||
| Q2 25 | $370.0M | $85.4M | ||
| Q1 25 | $358.4M | $63.6M | ||
| Q4 24 | $411.3M | $43.3M | ||
| Q3 24 | $396.9M | $32.3M | ||
| Q2 24 | $360.1M | $28.7M |
总债务APLSMAX
| Q1 26 | — | $163.5M | ||
| Q4 25 | — | $153.4M | ||
| Q3 25 | — | $155.7M | ||
| Q2 25 | — | $158.0M | ||
| Q1 25 | — | $160.2M | ||
| Q4 24 | — | $162.4M | ||
| Q3 24 | — | $164.7M | ||
| Q2 24 | — | $166.9M |
股东权益APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $4.2M | ||
| Q3 25 | $401.2M | $-29.8M | ||
| Q2 25 | $156.3M | $-3.8M | ||
| Q1 25 | $164.2M | $7.9M | ||
| Q4 24 | $228.5M | $2.4M | ||
| Q3 24 | $237.1M | $-8.4M | ||
| Q2 24 | $264.3M | $-24.4M |
总资产APLSMAX
| Q1 26 | — | $367.7M | ||
| Q4 25 | $1.1B | $383.8M | ||
| Q3 25 | $1.1B | $266.2M | ||
| Q2 25 | $821.4M | $249.4M | ||
| Q1 25 | $807.3M | $240.0M | ||
| Q4 24 | $885.1M | $262.4M | ||
| Q3 24 | $901.9M | $236.1M | ||
| Q2 24 | $904.5M | $198.2M |
负债/权益比APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 36.88× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 20.23× | ||
| Q4 24 | — | 68.31× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $-7.4M | ||
| Q3 25 | $108.5M | $23.6M | ||
| Q2 25 | $4.4M | $25.7M | ||
| Q1 25 | $-53.4M | $23.7M | ||
| Q4 24 | $19.4M | $14.5M | ||
| Q3 24 | $34.1M | $8.1M | ||
| Q2 24 | $-8.3M | $21.6M |
自由现金流APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $-7.5M | ||
| Q3 25 | $108.3M | $23.6M | ||
| Q2 25 | $4.4M | $25.5M | ||
| Q1 25 | $-53.4M | $23.6M | ||
| Q4 24 | $19.3M | $14.5M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | $-8.4M | $21.5M |
自由现金流率APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -2.6% | ||
| Q3 25 | 23.6% | 7.7% | ||
| Q2 25 | 2.5% | 10.2% | ||
| Q1 25 | -32.0% | 8.9% | ||
| Q4 24 | 9.1% | 4.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | -4.2% | 12.0% |
资本支出强度APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.1% |
现金转化率APLSMAX
| Q1 26 | — | — | ||
| Q4 25 | — | -0.24× | ||
| Q3 25 | 0.50× | 1.58× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.13× | ||
| Q3 24 | — | 0.85× | ||
| Q2 24 | — | 5.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MAX
暂无分部数据
